Viropharma, Inc. (VPHM) Cash Flow Statement

Click line-items for a historical chart and %

Net income
Non-cash share-based compensation expense	18.91M
Non-cash interest expense
Non-cash charge for contingent consideration
Deferred tax provision
Depreciation and amortization expense	26.66M
Other, net	-3.44M
Accounts receivable	13.32M
Inventory	-33.88M
Prepaid expenses and other current assets	-2.41M
Prepaid income taxes and taxes payable	11.43M
Other assets	-4.74M
Accounts payable	-5.48M
Accrued expenses and other current liabilities	-12.75M
Other non-current liabilities	2.37M
Net cash provided by operating activities
Purchase of Auralis, net of cash acquired
Purchase of Vancocin assets
Purchase of property, equipment and building improvements	-1.41M
Purchase of short-term investments	-49.81M
Maturities of short-term investments
Net cash used in investing activities
Payment for treasury shares acquired	0
Repayment of debt
Net proceeds from issuance of common stock	8.93M
Excess tax benefits from share-based payment arrangements	2.35M
Net cash (used in) provided by financing activities
Effect of exchange rate changes on cash
Net (decrease) increase in cash and cash equivalents
Cash and cash equivalents at beginning of period	175.52M
Cash and cash equivalents at end of period	205.59M

Entities mentioned with VPHM

View All Entities